Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Genotyping Assay Market worth $44.60 billion by 2031 - Exclusive Report by MarketsandMarkets™

prnewswire.com
TMO Thermo Fisher Scientific is a leading player in the genotyping assay market, benefiting from its extensive portfolio of PCR-based assays and molecular biology reagents. The company's strong position and continued investment in assay innovation are expected to drive revenue opportunities. ILMN Illumina is a dominant force in the genotyping assay market, holding a strong position with its microarray and sequencing platforms. The company's strategic collaborations and investments in AI-integrated risk models further bolster its prospects in precision medicine. AMGN While not directly mentioned as a player in genotyping assays, Amgen's involvement in drug discovery and development, which utilizes genotyping, suggests a potential indirect benefit from the market's growth. DHR Danaher Corporation participates in the genotyping assay market through its life sciences and diagnostics businesses. Its established presence and continued investment in assay innovation position it to benefit from market growth. BIO Bio-Rad Laboratories is listed as a key player in the genotyping assay market. Its involvement suggests it benefits from the market's growth, though specific details on its performance are not provided. AGNC Agilent Technologies, Inc. is identified as a key player in the genotyping assay market. Its participation indicates potential benefit from the market's expansion, but the article does not provide specific sentiment. PACB Pacific Biosciences is a key player in the genotyping assay market, likely benefiting from the growth in sequencing technologies. The article highlights the increasing demand for advanced sequencing platforms. ELMT Element Biosciences received significant funding to accelerate the commercialization of its genomic and multiomic technologies, indicating strong growth potential and positive market sentiment. REGN Regeneron's investment in Truveta's Series C financing to support the Truveta Genome Project, aimed at expanding DNA sequencing linked to EHRs, signals a bullish outlook on genetics-based drug discovery.

Genotyping Assay Market worth $44.60 billion by 2031 - Exclusive Report by MarketsandMarkets™ DELRAY BEACH, Fla., Nov. 3, 2026 /PRNewswire/ -- According to MarketsandMarkets™, the Genotyping Assay Market is projected to reach USD 44.60 billion by 2031 from USD 24.29 billion in 2026, at a CAGR of 12.9% during the forecast period.

Browse 444 market data Tables and 56 Figures spread through 370 Pages and in-depth TOC on 'Genotyping Assay Market - Global Forecast to 2031'

Genotyping Assay Market Size & Forecast:

Genotyping Assay Market Trends & Insights:

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=249958595

Market growth is driven by technological advances in DNA sequencing, the rising prevalence of genetic disorders, and the growing adoption of personalized medicine. The expanding use of genotyping in drug discovery and development, rising demand for molecular diagnostics, and expanding genomic research further support market growth. Additionally, advances in high-throughput genotyping platforms, automation, and bioinformatics solutions are expected to improve testing efficiency, broaden clinical and research applications, and support the adoption of genotyping technologies across the healthcare, pharmaceutical, and biotechnology industries.

The reagents & kits segment accounted for the largest share of the global genotyping assay market, by product, in 2025.

By product, the genotyping assays market is segmented into reagents & kits, genotyping services, instruments, and bioinformatics. The reagents & kits segment accounted for the largest share of the market in 2025, driven by recurring demand for PCR reagents, sequencing kits, genotyping arrays, and other consumables required for genetic analysis. Increasing adoption of pharmacogenomics, personalized medicine, and genomic research, along with the growing need for reliable, high-throughput genetic testing, supports the segment's leading position.

The sequencing segment is projected to be the fastest-growing technology segment in the genotyping assays market.

The global genotyping assays market is segmented by technology into PCR, sequencing, microarrays, and other technologies. During the forecast period, the sequencing segment is expected to grow strongly, driven by advances in next-generation sequencing (NGS), falling sequencing costs, and rising demand for comprehensive genetic variant detection. Expanding applications in rare disease research, oncology, pharmacogenomics, and precision medicine are further supporting adoption. Improvements in sequencing throughput, accuracy, and data analysis capabilities are expected to accelerate the adoption of sequencing-based genotyping solutions across research and clinical applications.

Inquiry Before Buying: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=249958595

North America accounted for the largest regional share of the global genotyping assays market in 2025.

The genotyping assays market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2025, North America accounted for the largest share of the global market, driven by a strong presence of pharmaceutical and biotechnology companies, advanced research infrastructure, and the widespread adoption of genomic technologies. The region benefits from substantial investments in genomics research, precision medicine, and drug discovery, as well as the presence of leading genotyping assay manufacturers and technology developers. The growing applications of genetic testing in disease diagnosis, pharmacogenomics, and personalized medicine, supported by collaborations among research institutions, healthcare organizations, and biotechnology companies, further strengthen the region's market position.

Key Players

Leading players in the Genotyping Assay companies include Thermo Fisher Scientific (US), Illumina, Inc. (US), QIAGEN N.V. (Germany), Roche Diagnostics (Switzerland), Danaher Corporation (US), Bio-Rad Laboratories, Inc. (US), Agilent Technologies, Inc. (US), Merck KGaA (Germany), Standard BioTools Inc. (US), Pacific Biosciences of California, Inc. (US), Oxford Nanopore Technologies plc (UK), Revvity, Inc. (US), Eurofins Scientific SE (Luxembourg), and Takara Bio Inc. (Japan).

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=249958595

Genotyping Assay Market - Investment and Funding Scenario

Investment Funding Context

The genotyping assays market continues to attract investment in genomic technologies, precision medicine, advanced sequencing platforms, and clinical genetic testing. In June 2026, Element Biosciences announced an expanded Series E financing round, including a USD 175 million investment from Samsung Electronics. The funding is intended to accelerate the commercialization of genomic and multiomic technologies, expand global operations, and advance product development for research and diagnostic applications. In July 2025, India-based MedGenome raised USD 47.5 million in Series E funding to expand access to genomic diagnostics and research services across India and other emerging markets. These investments reflect growing interest in scalable genomic platforms, clinical testing, and broader access to genetic analysis.

Revenue Shift Context

The genotyping assays market is gradually shifting toward integrated genomic solutions that combine assay reagents, high-throughput instruments, genetic testing services, and bioinformatics capabilities. Traditional revenue streams from PCR-based assays, genotyping kits, and laboratory instruments remain important, but demand is increasingly driven by pharmacogenomics, clinical genetic testing, population genomics, and sequencing-based research. In January 2025, Regeneron announced a USD 119.5 million investment in Truveta's Series C financing to support the Truveta Genome Project, which aims to expand DNA sequencing linked to electronic health records and accelerate genetics-based drug discovery.

This transition is also evident in strategic collaborations among technology developers, diagnostic companies, and pharmaceutical organizations. In December 2025, Illumina announced a collaboration and strategic investment in MyOme to advance whole-genome sequencing and AI-integrated risk models for disease prevention and precision medicine. These developments signal growing commercial interest in integrating genomic data, advanced analytical tools, and clinical applications. As pharmaceutical companies increasingly incorporate genetic information into drug development and treatment selection, demand is expected to expand across genotyping assays, consumables, sequencing platforms, and genomic data analysis solutions.

Mergers & Acquisitions

M&A activity in the genotyping assay ecosystem during 2025–2026 has been driven by companies seeking to expand genomic testing capabilities, acquire advanced genetic analysis technologies, strengthen bioinformatics platforms, and broaden access to clinical genomics markets. Buyers are prioritizing technologies that integrate genetic testing with AI-powered variant interpretation, sequencing-based diagnostics, and specialized genomic services, rather than relying solely on conventional consolidation among assay manufacturers.

GENOTYPING ASSAYS MARKET: MERGERS & ACQUISITIONS, JANUARY 2025–AUGUST 2026

MONTH & YEAR

DEAL TYPE

COMPANY 1

COMPANY 2

DESCRIPTION

April 2025

Acquisition

Eurofins Genomics (Luxembourg)

LGC Group's Sanger sequencing business (UK)

Eurofins Genomics acquired LGC's Sanger sequencing operations to expand its portfolio of genomic services, including sequencing and array genotyping capabilities.

May 2025

Acquisition

QIAGEN N.V. (Germany/Netherlands)

Genoox (Israel)

QIAGEN acquired Genoox for USD 70 million, with up to USD 10 million in additional milestone payments, adding its AI-powered Franklin platform for genetic variant interpretation and clinical genomics analysis.

September 2025

Acquisition agreement

SeqOne (France)

Congenica (UK)

SeqOne announced an agreement to acquire Congenica to strengthen its AI-powered genomic analysis capabilities and expand its international clinical genomics software business.

Company Revenue Share Details

The genotyping assays market is dominated by established life science and genomics companies, including Thermo Fisher Scientific Inc., Illumina, Inc., Danaher Corporation, and QIAGEN N.V., which collectively are estimated to account for approximately 45-50% of the market based on current study estimates. Thermo Fisher Scientific and Illumina are the leading companies in the competitive landscape, supported by extensive genotyping assay portfolios, established technology platforms, and a strong presence across research and clinical applications. These companies benefit from broad product offerings spanning reagents and kits, instruments, and genomic analysis technologies, as well as established relationships with pharmaceutical companies, diagnostic laboratories, and research institutions.

Competition is increasingly shifting beyond conventional assay portfolios toward high-throughput genotyping, automated workflows, sequencing-based analysis, and integrated bioinformatics solutions. Thermo Fisher Scientific continues to leverage its PCR-based assays and molecular biology reagents, while Illumina maintains a strong position with its microarray and sequencing platforms. QIAGEN focuses on molecular testing and sample preparation solutions, while Danaher participates through its life sciences and diagnostics businesses. Continued investment in assay innovation, precision medicine, and genomic data analysis is expected to shape competitive positioning and revenue opportunities across the genotyping assays market.

Browse Adjacent Market: Biotechnology Market Research Reports &Consulting

See More Latest Biotechnology Reports:

Next-generation Sequencing Market by Product (Reagents, Kits, Platforms), Service (CHIP Sequencing, Whole Genome, Methyl, RNA Sequencing), Technology (SBS, Nanopore), Workflow (Sequencing, Data Analysis), Application, Competition - Global Forecast to 2031

Molecular Diagnostics Market by Product & Service (Kits, Instruments, Software), Test Type (Lab, PoC), Sample (Blood, Urine), Technology (PCR, NGS, ISH), and Application (Infectious (Hepatitis, HIV, HAI, Flu), Cancer (Breast, Lung)) - Global Forecast to 2030

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.

Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.

The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.

MarketsandMarkets™ SalesPlay is an AI-driven Revenue Intelligence Co-Pilot designed to help revenue teams prioritize the right accounts, identify critical changes early, and surface opportunities ahead of demand, so pipeline builds naturally and deals close with greater consistency.

To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.

Contact:

Mr. Rohan Salgarkar

MarketsandMarkets™ INC.

1615 South Congress Ave.

Suite 103, Delray Beach, FL 33445

USA: +1-888-600-6441

Email: [email protected]

Visit Our Website: https://www.marketsandmarkets.com/

Research Insight: https://www.marketsandmarkets.com/ResearchInsight/genotyping-market.asp

Content Source: https://www.marketsandmarkets.com/PressReleases/genotyping.asp

SOURCE MarketsandMarkets